21 results
Common Causes of the Different Categories of Dizziness #Diagnosis #PrimaryCare #EM #IM #Differential #Dizziness #Vertigo #Disequilibrium
#PrimaryCare #EM ... #IM #Differential ... Lightheadedness #Table ... #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival #EBM ... #Osimertinib #NSCLC ... #Survival #NEJM
Differential Diagnosis of Jaundice, Presentation Pattern #Diagnosis #EM #IM #GI #Jaundice #Pattern #LFTs #Workup #Table #Differential
Pattern #Diagnosis #EM ... #IM #GI #Jaundice ... #LFTs #Workup #Table
Catecholamine Vasopressor Effect Sites and Indications #Pathophys #Management #EM #IM #PCC #Catecholamine #Comparison #Table #Epi #Norepi
Pathophys #Management #EM ... #IM #PCC #Catecholamine ... #Comparison #Table
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Non–Small-Cell Lung Cancer #EBM ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
to Trial Group #EBM ... #Neuro #IM #Fremanezumab ... AdverseEvents #NEJM ... #NEJM
Features of Noninferiority Studies #EBM #Noninferiority #Features #Table #NEJM
Noninferiority Studies #EBM ... Noninferiority #Features #Table ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #NEJM